|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | |||||||||||
| Cash | |||||||||||
| Short-term prepaid insurance | |||||||||||
| Prepaid expense | |||||||||||
| Cash and cash equivalents | |||||||||||
| Short-term marketable securities | |||||||||||
| Receivables from related parties | |||||||||||
| Prepaid expense and other current assets | |||||||||||
| Prepaid insurance – current portion | |||||||||||
| Total current assets | |||||||||||
| Long-term prepaid insurance | |||||||||||
| Long-term prepaid insurance | |||||||||||
| Marketable securities held in Trust Account | |||||||||||
| Long-term marketable securities | |||||||||||
| Property and equipment, net | |||||||||||
| Operating lease right-of-use asset | |||||||||||
| Other non-current assets | |||||||||||
| Restricted cash | |||||||||||
| Total assets | |||||||||||
| Current liabilities | |||||||||||
| Due to related party | |||||||||||
| Accounts payable and accrued expenses | |||||||||||
| Accounts payable | |||||||||||
| Accrued compensation and benefits | |||||||||||
| Accrued research and development liabilities | |||||||||||
| Accrued professional services | |||||||||||
| Payables to related parties | |||||||||||
| Notes Payable, Current | |||||||||||
| Related Party | |||||||||||
| Total notes Payable, Current | |||||||||||
| Operating lease liability, current | |||||||||||
| Other accrued liabilities | |||||||||||
| Participation right liability | |||||||||||
| Total current liabilities | |||||||||||
| Deferred underwriting fee | |||||||||||
| Operating lease liability, noncurrent | |||||||||||
| Total liabilities | |||||||||||
| Class A ordinary shares subject to possible redemption, 18,400,000 shares at redemption value of $10.68 and $10.46 per share as of June 30, 2025 and December 31, 2024, respectively | |||||||||||
| Class A Ordinary Shares | |||||||||||
| Total class A ordinary shares subject to possible redemption, 18,400,000 shares at redemption value of $10.68 and $10.46 per share as of June 30, 2025 and December 31, 2024, respectively | |||||||||||
| Stockholders' equity (deficit): | |||||||||||
| Preferred stock, value | |||||||||||
| Redeemable convertible preferred stock | |||||||||||
| Preferred Stock | |||||||||||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 80,234,557 and 79,991,768 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||
| Class A Ordinary Shares | |||||||||||
| Class B Ordinary Shares | |||||||||||
| Total common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 80,234,557 and 79,991,768 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||
| Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 4,600,000 shares issued and outstanding at March 31, 2024 and December 31, 2023 | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||
| Total stockholders' equity | |||||||||||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity |
Loading...